Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.65 |
| ▸ | TSHR | P16473 | 3/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.56 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31059180 | 0.93 | KDM4E (0.68) | KDM4ETSHRTDP1POLBNPSR1 | |
| SCHEMBL12819456 | 0.93 | KDM4E (0.68) | KDM4ETSHRTDP1POLBNPSR1 | |
| SCHEMBL31059181 | 0.93 | KDM4E (0.68) | KDM4ETSHRTDP1POLBNPSR1 | |
| SCHEMBL172594 | 0.90 | KDM4E (0.61) | KDM4ETSHRTDP1POLBNPSR1 | |
| SCHEMBL6033690 | 0.87 | KDM4E (0.67) | KDM4ETSHRTDP1POLBNPSR1 | |
| SCHEMBL654006 | 0.84 | HRH1 (0.61) | KDM4ETSHRTDP1POLBNPSR1 | |
| SCHEMBL13955394 | 0.84 | KDM4E (0.59) | KDM4ETSHRTDP1POLBNPSR1 | |
| SCHEMBL6785130 | 0.84 | KDM4E (0.59) | KDM4ETSHRTDP1POLBNPSR1 | |
| SCHEMBL655165 | 0.84 | KDM4E (0.59) | KDM4ETSHRTDP1POLBNPSR1 | |
| SCHEMBL13749778 | 0.84 | TDP1 (0.58) | KDM4ETSHRTDP1POLBNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9765091-B2 | Tetrahydropyrazolo [3,4-b] azepine derivatives and their use as allosteric modulators of metabotropic glutamate receptors | ADDEX PHARMA S.A. (CH) | 2017-09-19 | — | — | US | disclosed |
| US-20130267499-A1 | NOVEL TETRAHYDROPYRAZOLO [3,4-b] AZEPINE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2013-10-10 | — | — | US | disclosed |
| US-8236965-B2 | Benzimidazole derivatives and their use as a medicament | IPSEN PHARMA S.A.S. (FR) | 2012-08-07 | — | — | US | disclosed |
| EP-1255738-B1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES INC (US) | 2012-03-07 | — | — | EP | disclosed |
| US-7589067-B2 | 6, 11-bridged tricyclic macrolides | ENANTA PHARMACEUTICALS, INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-20090170922-A1 | Benzimidazole derivatives and their use as a medicament | SOCIETE DE CONSEILS DE RECHERECHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) | 2009-07-02 | — | — | US | disclosed |
| US-7495110-B2 | Benzimidazole derivatives and their use as GnRH antagonists | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 2009-02-24 | — | — | US | disclosed |
| US-20080039406-A1 | 3,6-BRIDGED TYLOSIN DERIVATIVES | ENANTA PHARMACEUTICALS, INC. | 2008-02-14 | — | — | US | disclosed |
| US-20070082853-A1 | 6, 11-bridged tricyclic macrolides | ENANTA PHARMACEUTICAL, INC. | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267499-A1 | NOVEL TETRAHYDROPYRAZOLO [3,4-b] AZEPINE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM4, GRM1, GRIK4 | KDM4E 414/4885TSHR 513/4885TDP1 3211/4885 |
| US-20090170922-A1 | Benzimidazole derivatives and their use as a medicament | GNRHR, FSHR, KISS1R | KDM4E 813/4885TSHR 64/4885TDP1 4048/4885 |
| US-20070082853-A1 | 6, 11-bridged tricyclic macrolides | CYP2B6, CYP2D6, ABCB11 | KDM4E 1806/4885TSHR 3740/4885TDP1 2159/4885 |
| US-20080039406-A1 | 3,6-BRIDGED TYLOSIN DERIVATIVES | ABCB11, ABCB1, CYP2B6 | KDM4E 1869/4885TSHR 4052/4885TDP1 1684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.